Zobrazeno 91 - 100
of 306
pro vyhledávání: '"Matthew R. Sydes"'
Publikováno v:
Trials
Trials, Vol 21, Iss 1, Pp 1-9 (2020)
Trials, Vol 21, Iss 1, Pp 1-9 (2020)
Background Despite the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) encouraging the use of risk-based monitoring for trials in 2013, there remains a lack of evidence-based guidelines on how to monitor. We surveyed the aca
Autor:
Carlos Diaz-Montana, Archie Macnair, Barbara E. Bierer, Annabelle South, Katie Gillies, Matthew R. Sydes, Talia Isaacs, William J. Cragg, Nalinie Joharatnam-Hogan, Andrew Copas, Cara Purvis, Claire Snowdon, Elizabeth C. James, Conor D. Tweed
Publikováno v:
PLoS Medicine, Vol 18, Iss 10, p e1003798 (2021)
PLoS Medicine
PLoS Medicine
Background Sharing trial results with participants is an ethical imperative but often does not happen. We tested an Enhanced Webpage versus a Basic Webpage, Mailed Printed Summary versus no Mailed Printed Summary, and Email List Invitation versus no
Autor:
O. Parikh, Mona Parmar, Silke Gillessen, J. M. Russell, Simon Chowdhury, Laura Murphy, Ian Pedley, Adrian Cook, Noel W. Clarke, Louise Brown, Matthew R. Sydes, William Cross, G. Attard, David Matheson, Anna Lydon, J. Bowen, Zafar Malik, Robert Jones, Chris Parker, Nicholas D. James
Publikováno v:
Annals of Oncology. 32:S1298
This is an accepted manuscript of an abstract published by Elsevier in Annals of Oncology on 01/09/2021, available online: https://doi.org/10.1016/j.annonc.2021.08.2098 The accepted version of the publication may differ from the final published versi
Autor:
Aziza Mirza, James R. Carpenter, Macey L. Murray, Sharon Love, Sarah Lensen, Carlos Diaz-Montana, Victoria Yorke-Edwards, Matthew R. Sydes
Publikováno v:
F1000Research. 10:815
Background: Feasibility trials are often undertaken to determine whether a larger randomised controlled trial (RCT) is achievable. In a recent review, 15 feasibility trials accessed routinely collected health data (RCHD) from UK national databases an
Autor:
Pei Loo Ow, Angel Garcia, Lesley Samuel, Rajarshi Roy, Adam McGeoch, D. Fyfe, W Saku, Simon Aird Grumett, Jonathan Nicoll, Jo Dent, Tom Samuel Waddell, Jo Webster, Christine Allmark, Tania Tillett, Colin Askill, Justin S. Waters, C. Handforth, Erica Beaumont, Vallipuram Vigneswaran, Sharon Ruddock, Nick Wadd, Syed Zubair, Kinnari Patel, Vanessa Potter, Daniel Propper, Olwyn Williams, Marc Jones, Kamalnayan Guptal, Peter Hall, Gareth Griffiths, Joseph Mano, Juan W. Valle, Sheela Rao, David A Cairns, Go Trial Investigators, Eszter Katona, Nick Maisey, Chris Twelves, Daniel Swinson, Nicholas Reed, Heike I. Grabsch, Joanne Askey, Jonathan Wadsley, Tom Roques, Sue Cheeseman, Stephen Falk, Louise Medley, Arshad Jamil, Emma Cattell, Victori Kunene, Matthew R. Sydes, Charles Candish, Claire Hobbs, Rebecca Herbertson, Jo Parkinson, Nicholas S. Reed, Louise Brook, Zuzana Stokes, Mohammed Khan, Ann Crossley, Elin Jones, George Bozas, Sebastian Cummins, Anirban Chatterjee, Michael Bennet, Helen Marshall, Pavel Bezecny, David Sherriff, Matthew T. Seymour, Lauren Gorf, Galina Velikova, Jean Gall, Kamposioras Konstantinos-Velios, Sally Clive, Eleanor James, Fiona Collinson, Dunca Wilkins, Simon Lord, Julia Brown, Serena Hilman, A. Robinson, Richard Ellis, Alaaeldin Shablak, Russell D Petty, Sherif Raouf, Helen Howard
Publikováno v:
Hall, P S, Swinson, D, A. Cairns, D, S. Waters, J, Petty, R, Allmark, C, Ruddock, S, Falk, S, Wadsley, J, Roy, R, Tillett, T, Nicoll, J, Cummins, S, Mano, J, Grumett, S, Stokes, Z, Konstantinos-Velios, K, Chatterjee, A, Garcia, A, Waddell, T, Guptal, K, Maisey, N, Khan, M, Dent, J, Lord, S, Crossley, A, Katona, E, Marshall, H, I. Grabsch, H, Velikova, G, Loo Ow, P, Handforth, C, Howard, H & T. Seymour, M 2021, ' Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal CancerThe GO2 Phase 3 Randomized Clinical Trial ', JAMA Oncology . https://doi.org/10.1001/jamaoncol.2021.0848
JAMA Oncology, 7(6), 869-877. American Medical Association
JAMA Oncology, 7(6), 869-877. American Medical Association
Importance: Older and/or frail patients are underrepresented in landmark cancer trials. Tailored research is needed to address this evidence gap. Objective: The GO2 randomized clinical trial sought to optimize chemotherapy dosing in older and/or frai
Autor:
E.J. Bass, F. Fransesca, M. Winkler, Matthew R. Sydes, A. Pope, Nimalan Arumainayagam, Emily Day, Natalia Klimowska-Nassar, Tim Dudderidge, Heminder Sokhi, B. Khoubehi, Thiagarajah Sasikaran
Publikováno v:
European Urology. 79:S1226
Autor:
Carrol Gamble, Peter Jüni, Tianjing Li, An-Wen Chan, Matthew R. Sydes, Anna Kearney, Karla Hemming
Publikováno v:
Trials, Vol 21, Iss 1, Pp 1-2 (2020)
TRIALS
TRIALS
Autor:
Claire Amos, A.M. Haran, Adnan Ali, Hassan Douis, Matthew R. Sydes, Alex Hoyle, Christopher D. Brawley, Mona Parmar, Y. Jain, J. Calvert, Noel W. Clarke, Nicholas D. James, T. Hambrock, G. Attard
Publikováno v:
Annals of Oncology. 31:S522-S523
Publikováno v:
The Lancet. 397:1624
Autor:
Matthew R. Sydes, Catherine Handforth, Janet E. Brown, Eugene V. McCloskey, C. Pezaro, Noel W. Clarke, Nicholas D. James, Jennifer Walsh
Publikováno v:
Annals of Oncology. 30:v334-v335
Background Androgen deprivation therapy (ADT) for prostate cancer (PC) increases fracture risk. In non-cancer populations, FRAX, a fracture risk assessment tool, is used routinely to calculate 10-year probability of major osteoporotic fracture (MOF;